Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium

European Journal of Surgical Oncology

Volumn 36, Issue 12, 2010, Pages 1195-1201

  Mhawech Fauceglia, P ^a   Herrmann, R F ^b   Kesterson, J ^a   Izevbaye, I ^a   Lele, S ^a   Odunsi, K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Disease outcome; Endometrioid adenocarcinoma; Prognostic factor; Uterine serous carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; MEGESTROL ACETATE; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXTERNAL BODY RADIATION THERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; UTERINE SEROUS CARCINOMA; VAGINA METASTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; EUROPE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 79952052748     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.09.010     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. CA Cancer J Clin 2007;57:43-66.
2. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007;31:979-87. (Pubitemid 47012293)
3. Kitchener HC, Trimble EL, Endometrial CancerWorking Group of the Gynecoloic Cancer Intergroup. Endometrial cancer state of the science meeting. Int J Gynecol Cancer 2009;19:134-40.
4. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005;97:755-63. (Pubitemid 40824643)
5. Naumann RW. Uterine papillary serous carcinoma state of the state. Curr Oncol Rep 2008;10:505-11.
6. Benito V, Lubrano A, Arencibia O, et al. Pure papillary serous tumors of the endometrium. A clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 2009;19:1364-9.
7. Faratian D, Stillie A,Busby-EarleRM,Cowie VJ,Monaghan H.Areview of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 2006;16:972-8. (Pubitemid 43886712)
8. Boruta II DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a society of gynecologic oncology (SGO) review. Gynecol Oncol 2009;115:142-53.
9. Tchabo NE, McCloskey S, Mashtare TL, et al. Treatment of earlystage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecol Oncol 2009;115:249-56.
10. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poor survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-6. (Pubitemid 43361894)
11. Fader AN, starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009;115:244-8.
12. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical- pathologic risk factors and outcome in clinical stage I and II carcinoma of the endoemtrium: a Gyneocologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
13. Figge DC, Otton PM, Tamimi HK, Greer BE. Treatment variables in the management of endometrial cancer. Am J Obstet Gynecol 1983; 146:495-500. (Pubitemid 13067477)
14. Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res 2007;27: 1213-8.
15. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-65. (Pubitemid 30217305)
16. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys 2002;54:79-85.
17. Boruto II DM, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas. Is there a survival difference? Cancer 2004;101:2214-21. (Pubitemid 39458676)
18. Creasman WT. Revision in classification by international federation of gynecology and obstetrics. Am J Obstet Gynecol 1992;167:857.
19. Van Wijk FH, Huiseshoven FJ, Abdulkadir L, Ewing PC, Burger CW. Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer 2006;16:1648-55. (Pubitemid 44060393)
20. Goff BA, Goodman A, Muntz HG, Fuller Jr AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237-40. (Pubitemid 24064377)
21. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987;60:2035-41.
22. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-8. (Pubitemid 24301898)
23. Corn BW, Lanciano RM, D'Agostino R, et al. The relationship of local and distant failure of endometrial adenocarcinoma: defining a clinical paradigm. Gynecol Oncol 1997;66:411-6. (Pubitemid 27388132)
24. Nofech-Mozes S, Ackerman I, Ghorab Z, et al. Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2008;129:912-7.
25. Vaknin Z, Ben-Ami I, Schneider D, Pansky M, Halperin R. A comparison of perioperative morbidity, perioperative mortality, and diseasespecific survival in elderly women (>or = 70 years) versus younger women (<70 years) with endometrioid endometrial cancer. Int J Gynecol Cancer 2009;19:879-83.